The Summary
What SmartShot Is
SmartShot is a design thesis for a wearable medical device that detects life-threatening physiological emergencies and delivers injectable medication autonomously, without requiring a conscious patient or a nearby bystander.
The medication exists. The emergency exists. The gap is the four minutes between them.
Remote Patient Monitoring is a $16 billion industry. It measures heart rate, SpO2, respiratory rate, skin temperature. It transmits that data to a dashboard. And when a patient is dying, the intervention is a phone call. Monitoring without intervention is observation, not care.
SmartShot introduces a new device category: Remote Medication Delivery (RMD). Where RPM detects and reports, RMD detects and delivers. The term is original to this project.
What It Does
SmartShot is a four-layer system:
- Sensor Array. Continuous monitoring via ECG, PPG, accelerometer, and temperature sensors. Detects the physiological onset of opioid-induced respiratory depression, anaphylaxis, cardiac events, and diabetic crisis.
- Decision Engine. On-device ML models analyze streaming sensor data and determine when to trigger medication delivery. All life-critical logic runs at the edge. No cloud dependency.
- Automatic Medication Injection (AMI). A miniaturized auto-injector delivers pre-loaded medication subcutaneously on command from the decision engine or control hub.
- Control Hub. A 24/7 staffed medical command center. Licensed paramedics and nurses monitor alerts and make the final injection decision when device confidence falls below the autonomous threshold. This creates a tiered response: autonomous, confirmed, escalated, or monitoring.
Four Conditions, Four Medications
Opioid Overdose → Naloxone. 54,045 deaths in 2024. 39-83% of fatal overdoses occur when the person is alone. Naloxone is OTC, well-understood, and has the highest false-positive tolerance. This is the beachhead.
Anaphylaxis → Epinephrine. 14 minutes from symptom to cardiac arrest. In three-quarters of pediatric deaths, epinephrine was either not given or given too late. In 37% of deaths, the auto-injector was not with the patient.
Cardiac Event → Nitroglycerin. 350,000 out-of-hospital cardiac arrests per year. Approximately 315,000 die. The Zoll LifeVest proves autonomous cardiac intervention is viable, but only for electrical therapy. No wearable delivers cardiac medication autonomously. Lasix ONYU delivers furosemide, but the patient has to trigger it.
Diabetic Crisis → Glucagon. Closed-loop insulin delivery is solved. Closed-loop glucagon for severe hypoglycemia is not. The sensor infrastructure exists. The rescue delivery does not.
Who It Helps
People who use opioids alone. Children with severe allergies whose EpiPen is locked in the nurse's office. Cardiac patients in rural areas, 40 minutes from the ER. Elderly patients in care facilities where medication errors affect 27% of residents. Anyone whose emergency medication exists but cannot reach them in time.
Stage of Development
SmartShot is pre-seed, pre-prototype intellectual property. The value is in the design thesis, the category naming, the beachhead analysis, and the regulatory pathway research.
- LLC registered (Kentucky, February 2024)
- EIN issued (99-1515832)
- Domain secured (smartshot.health)
- Canon documentation complete (6 documents)
- Brand identity established
What remains: prototype development, clinical data, FDA engagement, and funding. Each of those steps is detailed in the Canon documents that follow.
The Canon
Six documents comprise the complete argument:
- The Summary. This document.
- The Gap. Three scenarios, five barriers, and the structural argument for why RMD must exist.
- Technical Architecture. Sensor array, decision engine, injection mechanism, communication, control hub. Honest feasibility assessment at each layer.
- Regulatory Path. FDA classification, applicable standards, clinical trial design, realistic timeline. Plan for a decade.
- Market & Payment. Target markets, reimbursement strategy, payment models, unit economics, competitive landscape.
- Falsification & Open Questions. Every technical, regulatory, liability, and ethical risk that could kill the concept. Written before anyone asks.
Claims sourced. Numbers cited. The whole argument is designed to survive scrutiny.
What This Is Not
SmartShot is not a product. It is not a prototype. It is not a company with revenue. It is a design thesis backed by a registered entity, a complete documentation canon, and a clear-eyed assessment of what would need to be true for this device to exist.
The work done so far is the work that makes the next conversation possible.
Contact: joe.nalley@showyourwork.health